Kornimate/medical-research-clean huggingface dataset:
electroacupuncture therapy for change of pain in classical trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: the classical trigeminal neuralgia (ctn) is a common neuropathic pain in clinic by recurrent attacks of chronic sharp pain in the distribution of neuropathy branches of trigeminal neuralgia. with the lack of appropriate drug and surgery, acupuncture played a role in analgesia with its effective and few side effects. the study is designed to observe the therapeutic effect and safety of electroacupuncture (ea) in the treatment of ctn.

a total of 120 subjects with ctn who met the inclusion criteria will be included in the study. the subjects will be randomly divided into ea+ carbamazepine group, ea+placebo group, sham ea+carbamazepine group and sham ea+placebo group. the indexes of main outcome evaluation are 1)intensity of pain (evaluation of the pain by vas with 0-10 points) and 2)brief introduction of 2-week pain. the indexes of secondary outcome evaluation are 1) brief pain inventory-facial scale(bpi-facial); 2) patient global impression of change(pgic); 3) short-form mcgill pain questionnaire; 4) short- form 36 questionnaire. this study will evaluate whether ea has the advantage over carbamazepine in the immediate effect, long-term effect and post effect of the analgesia in ctn. at the same time, the study also will demonstrate whether ea has a synergistic effect with carbamazepine on the treatment of ctn, or even whether ea has an alternative effect on carbamazepine. furthermore, we will establish a standardized, effective and convenient therapy program of ea to promote according to the results.

Eligibility criteria:
inclusion criteria: 1. patients suffer from the pain with electric shock, shooting, stabbing occurs in one or more branches of the trigeminal nerve. 2. the visual analogue score(vas) baseline score ≥5, have a attack more than 3 times a day, at least 4 days a week. 3. 18 years ≤ age ≤ 80 years. 4. clear consciousness, have the ability of pain perception and resolution, can complete the basic communication. 5. signed informed consent and volunteered to participate in this study. exclusion criteria: 1. those patients with epilepsy, head injury or other related neurological diseases. 2. patients with serious heart, liver, kidney damage or cognitive impairment, aphasia, mental disorders, or unable to cooperate with the treatment. 3. combined with hypertension but poor control. 4. severe depressive with definitive diagnosis recently. 5. pregnant and lactating patients. 6. installing pacemakers. 7. for any other reason that is not suitable for the treatment of ea.

Keywords: classical trigeminal neuralgia electroacupuncture randomized controlled clinical trial
the use of low level laser therapy for wound healing in leprosy patients

Conditions: Leprosy

Summary: neuropathic ulcers are common sequelae of leprosy. the objectives of this study are to analyze the clinic-epidemiological characteristics of patients attended at one specialized dressing service from a leprosy-endemic region of the brazilian amazon and to evaluate the effect of low level laser therapy on wound healing of these patients.


Eligibility criteria:
inclusion criteria: * presented with neuropathic ulcer * attended at least 3 weekly appointments at the dressing service of uremc * completed specific multi-drug therapy for m. leprae * gave written informed consent to participate in the study exclusion criteria: * clinically detectable infection in the ulcer * use of drugs, like corticosteroids that could interfere with the wound healing process * use of special dressings like hydrocolloid, calcium alginate, activated carbon or any kind of therapeutic procedure different from that used routinely for both groups of study * non-attendance to therapeutic program (six sequential times or nine intercalated) * pregnancy * discomfort during treatment procedure

Keywords: leprosy ulcers laser
effect of counselıng

Conditions: Total Knee Replacement; Quality of Life; Nursing Caries

Summary: this study aims to determine the effect of counseling on quality of life and self-care agency for patients who are scheduled for tkr.

this is a quantitative study and has a quasi-experimental design with a control group. the sample of the study consisted of 79 patients including intervention (n=39) and control (n=40). the data are collected by the face-to-face interview method using patient identification form, quality of life scale, and self-care agency scale before surgery, and 6-8th weeks after discharge. face-to-face and telephone counseling were applied to individuals in the intervention group. the x2, t-test, one-factor variance analysis, and two-factor variance analysis were used in the analysis of the data.

Eligibility criteria:
inclusion criteria: * undergoing tka for the first time, being scheduled to have unilateral tka, having surgery for osteoarthritis, having no postoperative complications, fulfilment of discharge criteria after surgery, being aged 18 years or older, being conscious, orientation to place and time, having no hearing or speech problems, ability to understand and speak turkish, being at least literate, not being diagnosed with any psychiatric diseases and not having a history of cancer. exclusion criteria: * diagnoses of neurological (e.g. alzheimer's disease) and psychiatric disorders (e.g. schizophrenia) likely to affect cognitive functions, first accepting to participate in the study and then dropping out of the study, development of complications during follow-up (e.g. infection), unavailability when called and lost to follow-up.

Keywords: total knee replacement nursing counseling counseling quality of life self care agency
assessment of the utility of biomonitor to identify atrial fibrillation (af) in ablation candidates using precise af detection

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to evaluate the diagnostic utility of biotronik's subcutaneous cardiac rhythm monitor for the detection of af prior to an ablation procedure.

bio-precision is a post-market study investigating the utility of atrial fibrillation (af) detection using biotronik's subcutaneous cardiac rhythm monitor, biomonitor. the purpose of this study is to evaluate the diagnostic utility of biotronik's biomonitor for the detection and confirmation of af prior to an ablation procedure. study population includes patients with paroxysmal af being evaluated for an af ablation. holter monitoring for 48 hours will be performed after insertion of the biomonitor but prior to af ablation. this study will enroll up to 100 subjects, to obtain 60 usable holter recordings, at 5 study sites within the united states (u.s.). study subjects will be followed for three months after the completion of a 48 hr holter monitor.

Eligibility criteria:
inclusion criteria: * meet the indications for subcutaneous cardiac rhythm monitor insertion according to local regulations * patient is able to understand the nature of the study and provide written informed consent * inserted within the prior 30 days, or scheduled for insertion within 14 days, with biotronik's most current subcutaneous cardiac rhythm monitor * diagnosed with paroxysmal atrial fibrillation and being evaluated for an af ablation * agree to wearing a 48 hr holter monitor * able and willing to complete all study visits at the study site for the study duration * able and willing to use a cardiomessenger® and accepts home monitoring concept * age greater than or equal to 18 years exclusion criteria: * patient meets none of the indications for a biomonitor * patient is planned to have an ablation prior to biomonitor insertion or 48 hr holter monitoring visit * patient is currently diagnosed with long-standing persistent or permanent af * patient is enrolled in another study that may change or alter the cardiac rhythm that occurs prior to the completion of the holter * currently indicated for or implanted with a pacemaker, icd device, or hemodynamic monitoring system * life expectancy less than 6 months * patients reporting pregnancy at the time of enrollment for patients enrolled after biomonitor insertion: • r-wave sensing \<0.25 mv according to the most recent remote or in-person device interrogation available prior to enrollment after the pre-holter observation period but prior to 48 hr holter monitoring initiation, confirm the absence of the following exclusion criteria based on the remote interrogation collected at the end of the observation period: * no af episodes observed or transmitted during pre-holter observation period * r-wave sensing \<0.25 mv during pre-holter observation period as reported by the 24 hr mean or mean value since last follow-up
a multifaceted intervention to improve bleeding management among patients using oral anticoagulants (impact-bleeding)

Conditions: Bleeding

Summary: prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (oac) suffering major bleeding. randomization will be performed stratified by geographic region (southern/southeastern brazil versus other brazilian regions).

the group 1 in this trial will consist of a multifaceted bundle of instructions to sites about optimal management of bleeding, including transfusion thresholds and when indicated; laboratory assessment of coagulation when indicated; reversal agents when indicated, and tailored approach to restarting of oral anticoagulation and dosing adjustments among patients after bleeding episode. this bundle will be based on a society guideline on bleeding management from the american college of cardiology. the group 2 will be randomized to the standard of care. standard of care will be left to the discretion of the sites (clusters) participating in the study. all sites, including those from the control group, will be encouraged to follow local policies of blood product utilization and bleeding management.

Eligibility criteria:
inclusion criteria * age ≥ 18 years; * patients using chronic oac (that is, for 30 or more consecutive days) due to af/flutter, vte or other clinical indication and presenting with a major bleeding episode according to the definition of the international society of thrombosis and hemostasis (isth). exclusion criteria * patients with limitation to follow-up; * patients with do not resuscitate order at time of enrolment.
assessment of efficacy and safety of uk-390,957 in men with premature ejaculation

Conditions: Ejaculation

Summary: to determine whether uk-390,957 is an effective and safe treatment for premature ejaculation.


Eligibility criteria:
inclusion criteria: * premature ejaculation as defined by dsm-iv exclusion criteria: * history of erectile dysfunction
magnesium and vitamin d supplementation and cardiometabolic outcomes

Conditions: Overweight and Obesity; Vitamin D Deficiency; Magnesium Deficiency; Cardiovascular Risk Factor

Summary: the purpose of this study is to investigate the effects of a combined vitamin d and magnesium supplementation on parathyroid hormone and cardiometabolic health in persons living with obesity.

individuals living with obesity are at a higher risk of cardiometabolic abnormalities and high circulating parathyroid hormone. there is evidence suggesting that vitamin d may play a role in cardiovascular health outcomes; however, the research is currently inconclusive. magnesium is a cofactor of vitamin d metabolism, and the prevalence of concurrent vitamin d and magnesium deficiency is high. this study aims to investigate the effect of vitamin d and magnesium supplements in individuals who are overweight and obese on parathyroid hormone and cardiometabolic health.

Eligibility criteria:
inclusion criteria: * bmi range 25-40 kg/m2 * 30-70 years of age exclusion criteria: * presence of any acute illness in the past month * pre-existing chronic medical conditions or medications know to influence energy, vitamin d, magnesium and calcium metabolism, levels of blood glucose, lipids and blood pressure * individuals taking vitamin d and magnesium supplement greater than the recommended daily allowance * participants taking any medications or have disease known to influence calcium or bone metabolism
pancreatic adenocarcinoma gene environment risk study

Conditions: Pancreatic Cancer

Summary: after informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample. some participants may also be asked to provide a urine sample. individuals undergoing procedures that require collection of biological samples for clinical purposes may have these samples saved for research purposes. participants will also be asked for their permission for study investigators to access medical records and/or recontact them for updates to their medical and family histories. data and biospecimens will be stored for potential future research projects.


Eligibility criteria:
inclusion criteria: * histologically confirmed or ct confirmed diagnosis of pancreatic adenocarcinoma * subjects with abnormal imaging study (ct, mri, mrcp, eus) * control subjects with a clinical diagnosis of a pancreas, liver, or intestinal condition * control subject with acute pancreatitis * control subject with chronic pancreatitis * control subject with biliary obstruction * control subject with pancreatic cyst * member of a high risk family (≥ 1 close relative with pancreatic cancer) * healthy control (without any of the above conditions) exclusion criteria: * under the age of 18 years * unable to give informed consent * inability to travel to pittsburgh for in-person enrollment
comparison of tracheal ultrasound with capnography for intubation confirmation during cpr wearing ppe

Conditions: Cardiopulmonary Arrest

Summary: it is very important to ensure the tube placement in patients with cardiac arrest and unrecognized misplacement of endo-tracheal tube can lead to morbidity and mortality. in recent pandemic situations such as covid-19 (coronavirus disease-19), the number of cases of cardiopulmonary resuscitation with personal protective equipment (ppe) have increased. in those cases, existing methods such as auscultation and chest uprising have to be limited. quantitative waveform capnography is recommended as the gold standard for confirming correct endotracheal tube placement in the 2010 american heartassociation (aha) guidelines for cardiopulmonary resuscitation (cpr) and emergency cardiovascular care (ecc), but it has some well-known limitations in cardiac arrest patients. ultrasonography is a non-invasive, real-time diagnostic tool commonly used during resuscitation. especially, tracheal ultrasonography can be performed in real-time when the tube is passed through the trachea or esophagus. previous prospective studies revealed that tracheal ultrasonography could feasibly and rapidly confirm tracheal intubation during emergency intubation. there have already been several studies comparing the accuracy of tracheal ultrasound and capnography, but there was no study comparing the two tools under the constraints of ppe that is essential in pandemic situations as in this study. this study aimed to determine the accuracy of tracheal ultrasonography in assessing endotracheal tube position during cpr with ppe.

when patients in cardiopulmonary arrest enter a emergency room (er) or patients staying in a er have a cardiopulmonary arrest, participants perform intubation and cpr. when it is judged as a high-risk group with a high probability of droplet infection, all participants in resuscitation team should wear personal protective equipment. tracheal ultrasound and end-tidal carbon dioxide are used to confirm the placement of tube. the gold standard is the direct visualization using laryngoscope. the time it takes to confirm the placement of tube is also measured.

Eligibility criteria:
inclusion criteria: * 1. cardiopulmonary arrest patients receiving emergency intubation and cpr * 2. patients judged to need to wear ppe according to the judgement of the clinician exclusion criteria: * 1. sign for "do not resuscitate (dnr)" * 2. patients unable to perform tracheal ultrasound due to trauma of the site * 3. patients unable to perform tracheal ultrasound due to oropharynx cancer * 4. patients unable to perform tracheal ultrasound due to placement of tracheal cannula * 5. patients not used tracheal ultrasound for checking tube placement
renal and systemic vascular resistance in chronic kidney disease (ckd)

Conditions: Chronic Kidney Insufficiency; Hypertension; Vasodilation

Summary: patients with reduced kidney function have a higher risk of heart disease and death. studies have shown that blood vessels in patients with hypertension change with a decrease of lumen size and growth of the vessel wall. by treating patients with antihypertensive certain medication vessel lumen and walls normalize. treating hypertension in patients with chronic kidney disease slows the progression of kidney function loss. the aim is to compare different degrees of antihypertensive medication in patients with chronic kidney disease and hypertension will slow the progression of kidney loss.


Eligibility criteria:
inclusion criteria: * egfr 15-60 ml/min for at least 3 months * blood pressure \> 130 mmhg systolic og \>80 mmhg diastolic (patients without antihypertensive treatment or in treatment with beta-blockers, acei, arbs or ccb not in maximum dosi). * blood pressure \< 130 mmhg systolic og \< 80 mmhg diastolic (patients receiving beta-blockers, acei, arbs og ccb). * fertile women using safe contraceptives exclusion criteria: * ultrasound verified polycystic kidney disease (adpkd) * claustrophobia (mri scan). * contraindications to mri. * pregnancy or wish to become pregnant in the study period. * nephrotic syndrome with gross edema. * known allergy to any study medication. * blood pressure \< 130 mmhg systolic or \< 80 mmhg diastolic without antihypertensive treatment. * blood pressure \> 130 mmhg systolic or \> 80 mmhg diastolic and in maximum dosages of all three beta-blockers, acei (arbs) and ccb.
preop digifab in cabg to reduce ouabain levels and prevent aki

Conditions: Acute Kidney Injury

Summary: acute kidney injury (aki) occurs in up to 30% of patients undergoing coronary artery bypass graft (cabg) surgery, and often requires patients to go on dialysis. in patients needing dialysis, the risk of dying is very high.there are no known therapies to reduce the chance of developing kidney damage after heart surgery. there is evidence that patients with high levels of a substance called ouabain have an increased risk of developing kidney damage. this study is testing the hypothesis that giving a medication called digifab to lower the ouabain levels will reduce the risk of developing kidney damage after heart surgery.

this is a randomized double-blinded study investigating the role of digifab in patients with elevated risk of acute kidney injury undergoing cabg surgery. university of maryland medical center (ummc) and university of maryland st joseph medical center (umsjmc) patients who are undergoing cabg, meet the inclusion criteria and provide consent will be enrolled in this study and randomized to either digifab arm or the placebo (vehicle) arm. the study involves a follow up period of 72 hours post cabg surgery.

Eligibility criteria:
inclusion criteria: * undergoing coronary artery bypass surgery * glomerular filtration rate \> 15 history of diabetes mellitus or gfr \< 60 exclusion criteria: * allergy to digifab contrast dye within 3 days creatinine \> 25% above baseline

Keywords: coronary artery bypass surgery ouabain acute kidney injury
rifaximin in patients with monoclonal gammopathy

Conditions: IgA Monoclonal Gammopathy; IgG Monoclonal Gammopathy; IgM Monoclonal Gammopathy; Light Chain Deposition Disease; Monoclonal Gammopathy; Smoldering Waldenstrom Macroglobulinemia; Waldenstrom Macroglobulinemia; Gammopathy, Monoclonal; Gammopathy Igg

Summary: this trial studies how well rifaximin works in treating patients with monoclonal gammopathy. antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

primary objective: i. to evaluate the effect of a 2-week course of rifaximin on clonal immunoglobulin (ig) in patients with monoclonal gammopathy. secondary objectives: i. to evaluate safety and tolerability of a 2-week course of rifaximin. ii. to evaluate changes in stool microbiota by 16s ribosomal ribonucleic acid (rrna) gene (16s) sequencing. iii. to evaluate changes in gammopathy as assessed by changes in clonal ig and/or plasma cells. outline: patients receive rifaximin orally (po) thrice daily (tid) on days 1-14 in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed for 8 weeks.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of monoclonal gammopathy of undetermined significance based on international myeloma working group (imwg) criteria * patients will be enrolled into one of 3 cohorts: * cohort a: iga gammopathy * cohort b: igg gammopathy / or light chain gammopathy * cohort c: igm gammopathy / asymptomatic macroglobulinemia * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * patients who have received antibiotics within last 3 weeks * patients who are receiving any other investigational agents for gammopathy. patients with clinical myeloma requiring anti-myeloma therapy are also excluded * history of allergic reactions or intolerance attributed to rifaximin or compounds of similar chemical or biologic composition to antibiotic under study * the effects of rifaximin on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rifaximin administration